On February 28, the China-Singapore Guangzhou Knowledge City witnessed the inauguration of the China-Singapore Technology Innovation and Translational Medicine Center for Tumor Prevention and Treatment (TMC).
The China-Singapore Technology Innovation and Translational Medicine Center for Tumor Prevention and Treatment (TMC) is inaugurated in the China-Singapore Guangzhou Knowledge City.
This center, jointly established by Biosyngen and KCI Group, plays a significant role in providing a platform and serving as an innovation model for China-Singapore cooperation. The establishment of the TMC will effectively promote cooperation between the two countries in the field of cancer prevention and treatment.
The TMC is committed to building an open innovation platform for medical transformation in the field of cell and gene therapy. Its goal is to connect governmental organizations, hospitals, supply chains, and various stakeholders in the ecosystem. By integrating research, development, and production into a comprehensive industrial chain layout, the TMC aims to achieve clinical transformation and industrialization.
Loh Tuck Keat, Consul General of Singapore in Guangzhou, remarked, "The TMC cooperation between the two countries in the fields of innovation and science and technology will bring tangible mutual benefits to the people of China and Singapore."
Loh Tuck Keat, Consul General of Singapore in Guangzhou, delivers a speech.
As of now, the Knowledge City has attracted 96 Singaporean enterprises, with a total investment of nearly 18.5 billion RMB, highlighting its status as a hub for innovation and collaboration between China and Singapore.
Biosyngen was established in Singapore in 2016. As one of the first Singaporean companies to settle in the Knowledge City in 2017, it currently has four innovative drugs that will be launched on the market.
The experimenter is taking samples for testing.